Collaborative Arrangements and Licensing Agreements, GSK (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2010
Collaborative Arrangement and Licensing Agreement [Abstract]
Revenue	$ 787,647	$ 587,367	$ 810,456
GSK [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Upfront payment received				$ 35,000
Maximum amount of payments receivable over term of collaboration	260,000
Maximum amount of license fees over term of collaboration	25,000
Maximum amount of development milestone payments over term of collaboration	42,500
Maximum amount of regulatory milestone payments over term of collaboration	120,000
Maximum amount of sales milestone payments over term of collaboration	70,000
Next payment to be achieved	15,000
Revenue	15,000	0	$ 0
Deferred revenue	$ 0	$ 0
GSK [Member] | Revenue [Member] | Strategic Partner [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Concentration percentage	2.00%	0.00%	0.00%
GSK [Member] | Minimum [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Cumulative payments received	$ 105,000